CAMP4 Therapeutics Corp (NASDAQ: CAMP)’s stock price has soared by 13.02 in relation to previous closing price of 1.92. Nevertheless, the company has seen a gain of 24.00% in its stock price over the last five trading days. globenewswire.com reported 2025-04-28 that Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression
Is It Worth Investing in CAMP4 Therapeutics Corp (NASDAQ: CAMP) Right Now?
There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CAMP is 2.64M, and at present, short sellers hold a 13.17% of that float. The average trading volume of CAMP on May 06, 2025 was 43.26K shares.
CAMP’s Market Performance
CAMP’s stock has seen a 24.00% increase for the week, with a -28.38% drop in the past month and a -56.86% fall in the past quarter. The volatility ratio for the week is 10.20%, and the volatility levels for the past 30 days are at 15.93% for CAMP4 Therapeutics Corp The simple moving average for the last 20 days is 11.47% for CAMP’s stock, with a simple moving average of -62.01% for the last 200 days.
Analysts’ Opinion of CAMP
Piper Sandler, on the other hand, stated in their research note that they expect to see CAMP reach a price target of $18. The rating they have provided for CAMP stocks is “Overweight” according to the report published on November 05th, 2024.
JP Morgan gave a rating of “Overweight” to CAMP, setting the target price at $23 in the report published on November 05th of the previous year.
CAMP Trading at -38.72% from the 50-Day Moving Average
After a stumble in the market that brought CAMP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.36% of loss for the given period.
Volatility was left at 15.93%, however, over the last 30 days, the volatility rate increased by 10.20%, as shares sank -21.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -57.75% lower at present.
During the last 5 trading sessions, CAMP rose by +16.85%, in comparison to the 20-day moving average, which settled at $1.9405. In addition, CAMP4 Therapeutics Corp saw -58.43% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CAMP starting from Northpond Ventures II GP, LLC, who purchase 763,636 shares at the price of $11.00 back on Oct 15 ’24. After this action, Northpond Ventures II GP, LLC now owns 763,636 shares of CAMP4 Therapeutics Corp, valued at $8,399,996 using the latest closing price.
AH Equity Partners Bio I, L.L., the 10% Owner of CAMP4 Therapeutics Corp, purchase 727,272 shares at $11.00 during a trade that took place back on Oct 15 ’24, which means that AH Equity Partners Bio I, L.L. is holding 1,579,885 shares at $7,999,992 based on the most recent closing price.
Stock Fundamentals for CAMP
Current profitability levels for the company are sitting at:
- -0.05 for the present operating margin
- 0.36 for the gross margin
The net margin for CAMP4 Therapeutics Corp stands at -0.5. The total capital return value is set at -0.03.
Based on CAMP4 Therapeutics Corp (CAMP), the company’s capital structure generated 0.94 points at debt to capital in total, while cash flow to debt ratio is standing at -0.1.
Currently, EBITDA for the company is -8.72 million with net debt to EBITDA at -22.76. When we switch over and look at the enterprise to sales, we see a ratio of 1.3. The receivables turnover for the company is 2.25for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.92.
Conclusion
In summary, CAMP4 Therapeutics Corp (CAMP) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
